Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Risperidone for control of agitation in dementia patients
Autore:
Falsetti, AE;
Indirizzi:
Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Div Pharm & Practice, Brooklyn, NY 11201 USA Long Isl Univ Brooklyn NY USA 11201 rm & Practice, Brooklyn, NY 11201 USA Vet Affairs Med Ctr, Bronx, NY USA Vet Affairs Med Ctr Bronx NY USAVet Affairs Med Ctr, Bronx, NY USA
Titolo Testata:
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
fascicolo: 9, volume: 57, anno: 2000,
pagine: 862 - 874
SICI:
1079-2082(20000501)57:9<862:RFCOAI>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Keywords:
antipsychotic agents; basal ganglia diseases; dementia; depression; dosage; dosage schedules; geriatrics; psychomotor agitation; risperidone; toxicity;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
0
Recensione:
Indirizzi per estratti:
Indirizzo: Falsetti, AE Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci,Div Pharm & Practice, 75 De Kalb Ave, Brooklyn, NY 11201 USA Long Isl Univ75 De Kalb Ave Brooklyn NY USA 11201 11201 USA
Citazione:
A.E. Falsetti, "Risperidone for control of agitation in dementia patients", AM J HEAL S, 57(9), 2000, pp. 862-874

Abstract

Currently available research on the use of risperidone to manage agitationin patients with dementia is discussed. Dementia affects up to 70% of nursing-home patients, and more than 90% of them exhibit aggressive or agitated behavior or severe depression. Agitation includes combativeness, hyperactivity, disinhibition, wandering, and restlessness. Environmental interventions are preferred for mild symptoms; medications are the treatment of choice for severe manifestations. Traditional neuroleptics have been the mainstay of treatment for agitated behavior in persons with dementia, but these agents have limited efficacy and are associated with high rates of adverse effects, including worsening of already poor cognitive functioning. Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency ofextrapyramidal symptoms (EPS). Risperidone may also be useful for treatingacute agitation in patients with a high risk of EPS and for longterm treatment of "sundowning" (agitation and confusion starting in the late afternoon and worsening at night). A low initial dosage that is gradually adjusted upward is recommended. Risperidone appears effective in controlling agitation in patients with dementia and has a relatively benign adverse-effect profile, but more clinical trials are needed to elucidate its role for this indication.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 15:50:42